International Biotechnology Trust’s Amicus Therapeutics FOLD Stock Holding History

International Biotechnology Trust’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$1.09M	Buy	+90,000	New	+$1.16M	0.37%	48
2022 Q3	–	Sell	-1,017	Closed	-$94.6K	–	73
2022 Q2	$94.6K	Sell	1,017 -93,583	-99%	-$771K	0.99%	28
2022 Q1	$1.09M	Hold	94,600	–	–	0.25%	54
2021 Q4	$1.09M	Hold	94,600	–	–	0.24%	56
2021 Q3	$904K	Hold	94,600	–	–	0.22%	56
2021 Q2	$912K	Hold	94,600	–	–	0.24%	54
2021 Q1	$935K	Hold	94,600	–	–	0.25%	48
2020 Q4	$2.19M	Hold	94,600	–	–	0.6%	34
2020 Q3	$1.34M	Hold	94,600	–	–	0.43%	35
2020 Q2	$1.47M	Hold	94,600	–	–	0.49%	34
2020 Q1	$873K	Hold	94,600	–	–	0.4%	38
2019 Q4	$920K	Buy	94,600 +36,000	+61%	+$330K	0.33%	50
2019 Q3	$470K	Hold	58,600	–	–	0.22%	53
2019 Q2	$730K	Hold	58,600	–	–	0.27%	58
2019 Q1	$796K	Hold	58,600	–	–	0.29%	56
2018 Q4	$440K	Hold	58,600	–	–	0.27%	41
2018 Q3	$543K	Hold	58,600	–	–	0.26%	48
2018 Q2	$915K	Hold	58,600	–	–	0.35%	48
2018 Q1	$881K	Hold	58,600	–	–	0.34%	56
2017 Q4	$843K	Hold	58,600	–	–	0.3%	57
2017 Q3	$883K	Buy	+58,600	New	+$775K	0.34%	48
2017 Q1	–	Sell	-55,000	Closed	-$273K	–	62
2016 Q4	$273K	Buy	+55,000	New	+$381K	0.12%	49

Other funds holding FOLD

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

International Biotechnology Trust's FOLD Position: Q3 2023 in Review

International Biotechnology Trust opened a new position in Amicus Therapeutics (FOLD) in Q3 2023: 90,000 shares worth $1.09M. The stake represents 0.37% of the portfolio and ranks #48 among its holdings. This is a return to the name: International Biotechnology Trust previously reported a position in FOLD as recently as Q2 2022.

International Biotechnology Trust first reported a position in FOLD in Q4 2016 and has held it in 22 quarters since. The position peaked at $2.19M in Q4 2020. 228 funds tracked by Wall St. Rank hold FOLD as of Q3 2023.

International Biotechnology Trust held 90,000 shares of Amicus Therapeutics worth $1.09M as of Q3 2023.
Amicus Therapeutics was a new International Biotechnology Trust position in Q3 2023.
Amicus Therapeutics made up 0.37% of International Biotechnology Trust's portfolio in Q3 2023, its #48 holding.
International Biotechnology Trust first reported a position in Amicus Therapeutics in Q4 2016 and has held it in 22 quarters since.
International Biotechnology Trust's Amicus Therapeutics position peaked at $2.19M in Q4 2020.
228 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2023.

Based on International Biotechnology Trust's 13F filing for Q3 2023, filed 14 Nov 2023.